Improving the quality of randomized controlled trials in Chinese herbal medicine, part II: Control group design

Journal of Chinese Integrative Medicine

Volumn 4, Issue 2, 2006, Pages 130-136

  Bian, Zhao Xiang ^a   Moher, David ^b   Dagenais, Simon ^b   Li, You Ping ^c   Liu, Liang ^a   Wu, Tai Xiang ^c   Miao, Jiang Xia ^d  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c SICHUAN UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chinese herbal medicine; Control group; Methodology; Quality assessment; Randomized controlled trial

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HERBACEOUS AGENT; INSULIN; METFORMIN; PLACEBO; TOLBUTAMIDE;

CHINESE MEDICINE; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROL GROUP; EXPERIMENTAL DESIGN; HUMAN; INTERVENTION STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVER VARIATION; PATIENT COMPLIANCE; PATIENT SELECTION; QUALITY CONTROL; RANDOMIZATION; REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 33645326869     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20060205     Document Type: Review

References (16)

1. Su S. Atlas of Meteria Medica. Hefei: Anhui Science & Technology Publishing House, 1995.
2. PREVENTION of whooping cough by vaccination; a Medical Research Council investigation. BMJ 1951, (4721): 1463-1471.
3. Medical Research Council Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment for pulmonary tuberculosis. BMJ, 1948, ii: 769-782.
4. Shanghai collaborative group of clinical research on Buxux harlandii. Analysis of the effect of Buxux harlandii on coronary heart disease by double blind method. Report of 110 cases. J Tradit Chin Med, 1983, 24(5): 37-40.
5. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med, 1987, 317(3): 141-145.
6. Bian ZX, Li YP, Moher D, et al. Improving the quality of randomized controlled trials in Chinese herbal medicine, Part I: clinical design and methodology. Zhong Xi Yi Jie He Xue Bao, 2006, 4(2): 120-129.
7. Liu JP, Zhang M, Wang WY, et al. Chinese herbal medicines for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews, 2002, 3. http://www.update-software. com/Abstracts/ab003642. htm, 2005-10-08.
8. Hill AB. Medical ethics and controlled trials. BMJ, 1963, (5337): 1043-1049.
9. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med, 1994, 331(6): 394-398.
10. Declaration of Helsinki IV (1992). The Nazi doctors and the Nuremberg Code: human rights in human experimentation. New York: Oxford University Press, 1995. 339-342.
11. Guidance for industry: E 10 choice of control group and related issues in clinical trials. 2001. http://www.fda.gov/cder/guidance/4155fnl.htm, 2005-10-08.
12. Weijer C, Shapiro SH, Cranley Glass K. For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomized controlled trial. BMJ, 2000, 321(7263): 756-758.
13. Mann H, Djulbegovic B. Choosing a control intervention for a randomised clinical trial. Med Res Methodol, 2003, 3: 7.
14. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 1995, 273(5): 408-412.
15. Melnikow J, Kiefe C. Patient compliance and medical research: issues in methodology. J Gen Intern Med, 1994, 9(2), 96-105.
16. Vermeire E, Wens J, Van Royen P, et al. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database of Syst Rev, 2005, 18(2): CD003638.